- Home
- ARMK vs PCVX Comparison
ARMK vs PCVX Comparison
Compare ARMK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARMK | PCVX |
|---|---|---|
| Founded | 1959 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 6.1B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARMK | PCVX |
|---|---|---|
| Price | $37.44 | $47.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $46.50 | ★ $101.67 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ 23.23 | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $18,506,299,000.00 | N/A |
| Revenue This Year | $8.63 | N/A |
| Revenue Next Year | $5.93 | N/A |
| P/E Ratio | $30.67 | ★ N/A |
| Revenue Growth | ★ 6.35 | N/A |
| 52 Week Low | $29.92 | $27.66 |
| 52 Week High | $44.49 | $93.77 |
Technical Indicators
Market Signals| Indicator | ARMK | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 55.66 |
| Support Level | $37.69 | $42.40 |
| Resistance Level | $38.68 | $48.65 |
| Average True Range (ATR) | 0.66 | 1.61 |
| MACD | 0.05 | 0.22 |
| Stochastic Oscillator | 40.98 | 77.06 |
Price Performance
Historical ComparisonAbout ARMK Aramark
Aramark, founded in 1936 and headquartered in Philadelphia, Pennsylvania, operates as a food service company providing facility management and workplace solutions. The company primarily generates revenue from its North American food and support services segment, serving various clients including schools, healthcare facilities, and entertainment venues.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.